NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis → Discover How to Turn $10,000 into $1 Million (From Paradigm Press) (Ad) Free PODD Stock Alerts $200.45 -1.39 (-0.69%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$197.98▼$202.0450-Day Range$161.02▼$201.8452-Week Range$125.82▼$298.95Volume483,060 shsAverage Volume716,596 shsMarket Capitalization$14.04 billionP/E Ratio60.74Dividend YieldN/APrice Target$239.18 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside19.3% Upside$239.18 Price TargetShort InterestHealthy4.27% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.78Based on 20 Articles This WeekInsider TradingSelling Shares$2.34 M Sold Last QuarterProj. Earnings Growth20.90%From $3.11 to $3.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector28th out of 915 stocksSurgical & Medical Instruments Industry4th out of 98 stocks 3.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageInsulet has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insulet's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.27% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 29.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 2.7 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Insulet this week, compared to 9 articles on an average week.Search InterestOnly 5 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat Follows7 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,336,346.00 in company stock.Percentage Held by InsidersOnly 0.47% of the stock of Insulet is held by insiders.Read more about Insulet's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 20.90% in the coming year, from $3.11 to $3.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 60.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 60.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.90.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 19.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Insulet's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesJune 12 at 6:15 AM | insidertrades.comInsulet Co. (NASDAQ:PODD) SVP Mark N. Field Sells 2,131 SharesMay 31, 2024 | insidertrades.comTimothy J. Scannell Sells 3,300 Shares of Insulet Co. (NASDAQ:PODD) StockJune 13 at 5:44 AM | americanbankingnews.comMark N. Field Sells 2,131 Shares of Insulet Co. (NASDAQ:PODD) StockJune 12 at 7:32 AM | americanbankingnews.comInsulet Co. (NASDAQ:PODD) Director Timothy J. Scannell Sells 7,000 Shares of StockJune 12 at 2:22 AM | americanbankingnews.comInsulet (NASDAQ:PODD) Given Mixed Rating at OTR GlobalJune 11, 2024 | gurufocus.comInsider Sale: Director Timothy Scannell Sells 7,000 Shares of Insulet Corp (PODD)June 11, 2024 | seekingalpha.comInsulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023June 7, 2024 | americanbankingnews.comCritical Comparison: Insulet (NASDAQ:PODD) vs. Bluejay Diagnostics (NASDAQ:BJDX)May 28, 2024 | businesswire.comInsulet to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | finance.yahoo.comInsulet Corporation (PODD)May 19, 2024 | investorplace.comFollow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit GainsMay 14, 2024 | au.investing.comBlue Orca goes short Insulet on undisclosed preliminary injunction defeatMay 14, 2024 | finance.yahoo.comWall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?May 14, 2024 | finance.yahoo.comWill Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems MarketMay 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)May 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)May 13, 2024 | benzinga.comWhat the Options Market Tells Us About InsuletMay 13, 2024 | markets.businessinsider.comInsulet (PODD) Gets a Hold from Stifel NicolausMay 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)May 12, 2024 | finance.yahoo.comResults: Insulet Corporation Beat Earnings Expectations And Analysts Now Have New ForecastsMay 12, 2024 | msn.comStreet calls of the week: Micron upgraded, downgrade for ZoomInfoMay 10, 2024 | markets.businessinsider.comInsulet Corporation: Strong Q1 Performance and Positive Growth Outlook Affirm Buy RatingMay 10, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)May 10, 2024 | finance.yahoo.comInsulet Corp (PODD) Reports Strong Q1 2024 Results and Raises Full-Year GuidanceMay 10, 2024 | finance.yahoo.comInsulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call TranscriptSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/15/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$239.18 High Stock Price Target$330.00 Low Stock Price Target$184.00 Potential Upside/Downside+19.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio60.74 Forward P/E Ratio64.45 P/E Growth3.63Net Income$206.30 million Net Margins13.14% Pretax Margin13.75% Return on Equity34.06% Return on Assets9.08% Debt Debt-to-Equity Ratio1.72 Current Ratio3.74 Quick Ratio2.75 Sales & Book Value Annual Sales$1.70 billion Price / Sales8.27 Cash Flow$3.77 per share Price / Cash Flow53.19 Book Value$10.49 per share Price / Book19.11Miscellaneous Outstanding Shares70,040,000Free Float69,711,000Market Cap$14.04 billion OptionableOptionable Beta1.14 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.88MMs. Lauren Budden (Age 49)Group VP, Chief Accounting Officer & Controller Comp: $794.05kMr. Mark Field (Age 53)Senior VP & CTO Comp: $954.14kMr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $1.02MMs. Shacey Petrovic (Age 51)Director & Advisor Comp: $28.57kMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $1.14MMs. Ana Maria Chadwick (Age 52)Executive VP, CFO & Treasurer Mr. Prem Singh (Age 47)Senior Vice President of Global Operations Ms. Deborah R. Gordon CPA (Age 53)Vice President of Investor Relations Ms. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance More ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCREdwards LifesciencesNYSE:EWDexComNASDAQ:DXCMIDEXX LaboratoriesNASDAQ:IDXXView All CompetitorsInsiders & InstitutionsTimothy J ScannellSold 7,000 sharesTotal: $1.33 M ($190.51/share)Mark N FieldSold 2,131 sharesTotal: $405,806.33 ($190.43/share)DekaBank Deutsche GirozentraleBought 770 shares on 6/4/2024Ownership: 0.017%Timothy J ScannellSold 3,300 sharesTotal: $596,970.00 ($180.90/share)Teachers Retirement System of The State of KentuckyBought 6,754 shares on 5/28/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 18 analysts have issued 12-month price objectives for Insulet's stock. Their PODD share price targets range from $184.00 to $330.00. On average, they expect the company's stock price to reach $239.18 in the next year. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2024? Insulet's stock was trading at $216.98 at the beginning of the year. Since then, PODD stock has decreased by 7.6% and is now trading at $200.45. View the best growth stocks for 2024 here. Are investors shorting Insulet? Insulet saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 2,990,000 shares, a decrease of 29.8% from the May 15th total of 4,260,000 shares. Based on an average daily trading volume, of 839,500 shares, the short-interest ratio is presently 3.6 days. View Insulet's Short Interest. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, May, 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.34. The medical instruments supplier had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a trailing twelve-month return on equity of 34.06%. The firm's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period last year, the business posted $0.23 earnings per share. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Fidelity Disruptive Medicine ETF (FMED), Goldman Sachs Future Health Care Equity ETF (GDOC), Tema Cardiovascular and Metabolics ETF (HRTS), Invesco Focused Discovery Growth ETF (IVDG) and First Trust Indxx Medical Devices ETF (MDEV). What guidance has Insulet issued on next quarter's earnings? Insulet updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $456.0 million-$467.9 million, compared to the consensus revenue estimate of $457.8 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.71%), Capital Research Global Investors (10.80%), Baillie Gifford & Co. (2.06%), Clearbridge Investments LLC (1.81%), William Blair Investment Management LLC (1.36%) and Westfield Capital Management Co. LP (0.67%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, Luciana Borio, Mark N Field, Michael P Spears, Prem Singh, Shacey Petrovic, Timothy J Scannell and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.